Coloplast maintained its full-year 2024/25 guidance of approximately 7% organic sales growth and an EBIT margin of 27-28%. This outlook incorporates the DKK80 million impact from the Wound Care ...

Investing.com -- Coloplast A/S (CSE: COLOb) on Tuesday said its net profit fell 26% in the first nine months of its 2024/25 financial year, as extraordinary tax expenses tied to its Kerecis unit ...

(Bloomberg) — Coloplast A/S fired its chief executive officer to restore investor confidence after the medical equipment maker failed to deliver sufficient shareholder returns. That’s according to ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...

Coloplast's stock price has declined by 25% since April 2023, making it more attractive but still overvalued based on fundamentals and valuation multiples. Recent quarterly results show revenue growth ...

Three in five of the UK’s largest media companies reported growing news and information revenue in their most recent full-year accounts, Press Gazette’s latest top 50 ranking shows. Collectively the ...

On Wednesday, UBS analyst changed the rating for Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY) from Sell to Neutral, maintaining a price target of DKK858.00. The revision follows a reassessment of ...

Based in Denmark, Coloplast is a leader in global ostomy and continence care. The firm has made inroads into the concentrated urology and fragmented woundcare markets, but it remains a peripheral ...

On Monday, Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY) received an upgrade in its stock rating from Barclays (LON:BARC), moving from Equalweight to Overweight. Accompanying this upgrade, the ...

More than 176,000 people in the UK are living with a stoma, according to NHS data Coloplast has announced the launch of its world-first digital leakage notification system, Heylo, to benefit patients ...